Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Certepetide - Lisata Therapeutics

Next Previous
Drug Profile

Certepetide - Lisata Therapeutics

Alternative Names: CEND-1; Internalised-arginylglycylaspartic Acid Cyclic Peptide; iRGD; LSTA-1; QLC-12102

Latest Information Update: 11 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator DrugCendR
  • Developer Australasian Gastro-Intestinal Trials Group; Lisata Therapeutics; National Health and Medical Research Council Clinical Trials Centre; Qilu Pharmaceutical; The University of Kansas Cancer Center; University of Sydney
  • Class Antineoplastics; Cyclic peptides; Peptides
  • Mechanism of Action Integrin alphaV antagonists; Neuropilin-1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Osteosarcoma; Glioma; Cholangiocarcinoma; Pancreatic cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Adenocarcinoma; Glioblastoma; Pancreatic cancer; Solid tumours
  • Phase I/II Colorectal cancer; Gastrointestinal cancer

Most Recent Events

  • 26 May 2026 Lisata Therapeutics terminates phase-II clinical trials in Solid tumours (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Recurrent) in USA, Spain, Canada, Australia (IV) to allow analysis of the results (NCT05712356)
  • 27 Jan 2026 Qilu Pharmaceutical terminates its licence for Certepetide in Mainland China, Hong Kong, Macau, and Taiwan
  • 17 Oct 2025 Efficacy and adverse events data form phase IIb ASCEND trial in Pancreatic cancer presented at the 50th European Society for Medical Oncology Congress (ESMO-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top